Literature DB >> 10403692

Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients.

M K Martel1, R K Ten Haken, M B Hazuka, M L Kessler, M Strawderman, A T Turrisi, T S Lawrence, B A Fraass, A S Lichter.   

Abstract

Tumor control probability (TCP) model calculations may be used in a relative manner to evaluate and optimize three-dimensional (3-D) treatment plans. Using a mathematical model which makes a number of simplistic assumptions, TCPs can be estimated from a 3-D dose distribution of the tumor given the dose required for a 50% probability of tumor control (D50) and the normalized slope (gamma) of the sigmoid-shaped dose-response curve at D50. The purpose of this work was to derive D50 and gamma from our clinical experience using 3-D treatment planning to treat non-small cell lung cancer (NSCLC) patients. Our results suggest that for NSCLC patients, the dose to achieve significant probability of tumor control may be large (on the order of 84 Gy) for longer (> 30 months) local progression-free survival.

Entities:  

Mesh:

Year:  1999        PMID: 10403692     DOI: 10.1016/s0169-5002(99)00019-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  77 in total

Review 1.  Radiation dose effect in locally advanced non-small cell lung cancer.

Authors:  Feng-Ming Spring Kong; Jing Zhao; Jingbo Wang; Corrine Faivre-Finn
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

Review 3.  Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation.

Authors:  Nergiz Dağoğlu; Şule Karaman; Alptekin Arifoğlu; Seden Küçücük; Ethem N Oral
Journal:  Balkan Med J       Date:  2014-12-01       Impact factor: 2.021

4.  The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices.

Authors:  Abdulhamid Chaikh; Jacques Balosso
Journal:  Transl Lung Cancer Res       Date:  2017-06

5.  Breathing-synchronized delivery: a potential four-dimensional tomotherapy treatment technique.

Authors:  Tiezhi Zhang; Weiguo Lu; Gustavo H Olivera; Harry Keller; Robert Jeraj; Rafael Manon; Minesh Mehta; Thomas R Mackie; Bhudatt Paliwal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-06-14       Impact factor: 7.038

6.  Dose-mass inverse optimization for minimally moving thoracic lesions.

Authors:  I B Mihaylov; E G Moros
Journal:  Phys Med Biol       Date:  2015-04-24       Impact factor: 3.609

7.  Update: modern approaches to the treatment of localized esophageal cancer.

Authors:  James Welsh; Arya Amini; Anna Likhacheva; Jeremy Erasmus J; Daniel Gomez; Marta Davila; Reza J Mehran; Ritsuko Komaki; Zhongxing Liao; Wayne L Hofstetter; Jeffrey Lee H; Manoop S Bhutani; Jaffer A Ajani
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

8.  Repopulation of interacting tumor cells during fractionated radiotherapy: stochastic modeling of the tumor control probability.

Authors:  Hatim Fakir; Lynn Hlatky; Huamin Li; Rainer Sachs
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

9.  Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what?

Authors:  Rameses Sroufe; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2015-08

10.  Dose-guided radiotherapy for lung tumors.

Authors:  Angelo Piermattei; Andrea Fidanzio; Savino Cilla; Francesca Greco; Luigi Azario; Domenico Sabatino; Mattia Grusio; Mariella Cozzolino; Vincenzo Fusco
Journal:  Med Biol Eng Comput       Date:  2009-12-10       Impact factor: 2.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.